GE Healthcare received U.S. Food and Drug Administration (FDA) clearance for its Discovery IGS 740, a new rail-free mobile angiography system with a 41x41 cm detector.
The past year saw the release of several new, innovative technologies to improve nuclear imaging in both positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
If you enjoy this content, please share it with a colleague
April 6, 2014 — iCAD, a provider of advanced image analysis, workflow solutions and radiation therapy, reported it has entered into an agreement effective April 28, 2014, that terminates the revenue-sharing component of iCAD’s debt facility agreement with Deerfield Management Company LP, dated Dec. 29, 2011, in exchange for a cash payment of $4.1 million to Deerfield.
May 6, 2014 — DICOM Grid is expanding its cloud portfolio with new hybrid image management solutions at the 2014 annual meeting of the Society for Imaging Informatics in Medicine (SIIM) in Long Beach, Calif.
May 6, 2014 — Medtronic announced the first U.S. implant of the Evera MRI SureScan implantable cardioverter-defibrillator (ICD) system, following U.S. Food and Drug Administration (FDA) approval for its investigational device exemption (IDE) application and pivotal clinical trial protocol.
May 6, 2014 — Siemens Healthcare announced the U.S. Food and Drug Administration (FDA) has cleared the Artis one angiography system, optimized for broad clinical utilization. The Artis one is designed for routine interventions, including revascularizations of peripheral vessel occlusions, functional tests of dialysis shunts in patients with kidney failure, diagnostic or minimally invasive angiographic treatment of narrowed coronary arteries, and pacemaker implantations.
If you enjoy this content, please share it with a colleague
As an editor attending clinical symposiums and always on the lookout for new trends in technology, I sometimes find myself wondering if what I see is actually the reality on the ground for most clinicians. A recent example of this has been the implementation and use of clinical decision support (CDS) software to ensure physicians are following appropriate use criteria (AUC).
The American Society for Radiation Oncology (ASTRO) is concerned by the Medicare Evidence Development and Coverage Advisory Committee’s (MEDCAC) April 30, 2014 recommendation to the Centers for Medicare and Medicaid Services (CMS) that adults at high risk for lung cancer should not receive Medicare coverage of annual, low-dose computed tomography (LDCT) screening.
If you enjoy this content, please share it with a colleague
